CD8A and neoplasm: The results showed that RT increased the percentage of CD8+ positive CAR-T cells (CD3 + CD8 + EGFR + ) and effector CAR-T cells (CD3 + EGFR + CD45RA + CCR7-) in peripheral blood 7 days after CAR-T injection, highlighting the enhanced anti-tumor activity of the synergy therapy.